<DOC>
	<DOCNO>NCT01132235</DOCNO>
	<brief_summary>The purpose study evaluate efficacy re-treatment etanercept 50mg subcutaneous injection twice weekly 12 week subject previously treat etanercept efficacy diminish .</brief_summary>
	<brief_title>An Open-label Study Evaluate Efficacy Re-treatment Patients With History Etanercept Use</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects psoriasis previously treat etanercept minimum 6 month discontinue treatment due loss efficacy . Every attempt make obtain loss efficacy history subject 's medical chart ; etanercept commence terminate description patient 's psoriasis termination detail new treatment commence . Subjects must fail late psoriasis treatment period three month . This measure PGA ≥ 3 . There specific requirement prior treatment etanercept occur requirement type treatment ( ) use initial subsequent treatment . Are ≥ 18 year age PGA ≥ 3 BSA minimum 5 % Tuberculosis inclusion criterion Have history latent active TB prior screen . Have sign symptom suggestive active TB upon medical history and/or physical examination . Have recent close contact person active TB . Within 1 month prior first administration study negative tuberculin skin test . The ability give write informed consent comply study procedure . Current enrollment investigational device investigational drug trial ( ) , receipt investigational agent ( ) within 28 day baseline visit . Known hypersensitivity Enbrel® ( etanercept ) component know antibody etanercept . Latex sensitivity [ NB : applicable use prefilled syringe prefilled SureClick™ autoinjector presentation ] Prior concurrent use cyclophosphamide therapy Concurrent sulfasalazine therapy . A positive HBV test know history immunosuppressing disease . Any mycobacterial disease high risk factor tuberculosis ( TB ) , family member TB , positive purify protein derivative ( PPD ) take antituberculosis medication . Active chronic infection within 4 week screen visit , screen baseline visit . History listeriosis , histoplasmosis , chronic active Hepatitis B infection Hepatitis C , human immunodeficiency virus ( HIV ) infection , immunodeficiency syndrome , chronic recur infection active TB , opportunistic infection If etanercept previously discontinue due serious adverse event Severe comorbidities ( diabetes mellitus require insulin ; CHF severity ; myocardial infarction , cerebrovascular accident transient ischemic attack within 6 month screen visit ; unstable angina pectoris ; uncontrolled hypertension ( sit systolic BP &lt; 80 mm Hg &gt; 160 diastolic BP &gt; 100 mm Hg ) ; oxygendependent severe pulmonary disease ; history cancer within 5 year [ resect cutaneous basal squamous cell carcinoma skin situ cervical cancer ] ) Systemic lupus erythematosus , history multiple sclerosis , transverse myelitis , optic neuritis seizure disorder . Use live vaccine 90 day prior screen visit , concurrent use live vaccine . Any condition circumstance judge patient 's physician [ investigator medically qualify study staff ] render clinical trial detrimental otherwise unsuitable patient 's participation . Female subject pregnant , nurse planning pregnancy ( men woman ) use acceptable method birth control trial ( hormonal , barrier , abstinence ) . Women breast feeding History noncompliance therapy . History alcohol abuse within last 12 month Concurrent use anakinra Subjects discontinue drug 2 week prior baseline visit study ; A two week wash period appropriate would unethical expect subject whose disease flare remain untreated long period time . The first dose etanercept administer two week last biologic dose . Immunosuppressants , antimalarial , sulfasalazine . Other AniTNFs Cyclosporine Efalizumab Azathioprine Hydroxyurea Live vaccine Tacrolimus Oral retinoids ( isotretinoin , acitretin , bexarotene ) Ultra violet light therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>